In the largest settlement involving a pharmaceutical company, the British drugmaker GlaxoSmithKline agreed to plead guilty to criminal charges and pay $3 billion in fines for promoting its best-selling antidepressants for unapproved uses and failing to report safety data about a top diabetes drug, federal prosecutors announced Monday.
The fine against GlaxoSmithKline over Paxil, Wellbutrin and Avandia makes this year a record for money recovered by the federal government under its so-called whistle-blower law.
In May, Abbott Laboratories settled for $1.6 billion over its marketing of the antipsychotic drug Depakote. And an agreement with Johnson & Johnson that could result in a fine of as much as $2 billion is said to be imminent over its off-label promotion of another antipsychotic drug Risperdal.
No individuals have been charged in any of the cases. Even so, the Justice Department contends the prosecutions are well worth the effort —
http://www.nytimes.com/2012/07/03/b...ees-to-pay-3-billion-in-fraud-settlement.html
The fine against GlaxoSmithKline over Paxil, Wellbutrin and Avandia makes this year a record for money recovered by the federal government under its so-called whistle-blower law.
In May, Abbott Laboratories settled for $1.6 billion over its marketing of the antipsychotic drug Depakote. And an agreement with Johnson & Johnson that could result in a fine of as much as $2 billion is said to be imminent over its off-label promotion of another antipsychotic drug Risperdal.
No individuals have been charged in any of the cases. Even so, the Justice Department contends the prosecutions are well worth the effort —
http://www.nytimes.com/2012/07/03/b...ees-to-pay-3-billion-in-fraud-settlement.html
